石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准

智通财经2025-12-12

智通财经APP讯，石药集团(01093)发布公告，集团开发的盐酸伊立替康脂质体注射液(商品名：多恩益®)的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的新适应症为与奥沙利铂、5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于转移性胰腺癌患者的一线治疗。该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细胞学确诊的不可切除的局部晚期或转移性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590703195?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-12 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590703195","market":"us","top_or_hot":-1,"title":"石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，集团开发的盐酸伊立替康脂质体注射液(商品名：多恩益®)的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的新适应症为与奥沙利铂、5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于转移性胰腺癌患者的一线治疗。该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细胞学确诊的不可切除的局部晚期或转移性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1380988.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-12 18:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1380988.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，集团开发的盐酸伊立替康脂质体注射液(商品名：多恩益®)的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的新适应症为与奥沙利铂、5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于转移性胰腺癌患者的一线治疗。该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细胞学确诊的不可切除的局部晚期或转移性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1380988.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0008368742.USD","symbol_name":"首域中国增长基金I Acc","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1380988.html","article_id":"2590703195","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590703195","pubTimestamp":1765535073,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，石药集团 发布公告，集团开发的盐酸伊立替康脂质体注射液的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首次获批用于胰腺癌一线治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1191":"制药","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1515":"抗疫概念","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","01093":"石药集团","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC"},"translate_title":"CSPC (01093): Doenyi ® (Irinotecan Hydrochloride Liposome Injection) New Indication Approved for Marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5},"content_text":"智通财经APP讯，石药集团(01093)发布公告，集团开发的盐酸伊立替康脂质体注射液(商品名：多恩益®)的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的新适应症为与奥沙利铂、5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于转移性胰腺癌患者的一线治疗。该适应症的获批主要是基于一项关键临床试验，入组对象为未接受过系统性抗肿瘤治疗、经组织学或细胞学确诊的不可切除的局部晚期或转移性胰腺癌患者。在2024年美国临床肿瘤学会(ASCO)年会已披露的结果显示，该产品用于晚期胰腺癌一线治疗可显著延长无进展生存期(PFS)(风险比(HR)为0.55，疾病进展或死亡风险降低45%)，在客观缓解率(ORR)、缓解持续时间(DOR)及总生存期(OS)方面均呈现获益趋势，且安全性良好，相比普通制剂实现了减毒增效的作用。该产品已于2023年9月15日在中国获批上市，首个获批的适应症为与5-氟尿嘧啶(5-FU)和亚叶酸(LV)联合用于接受吉西他滨治疗后进展的转移性胰腺癌患者，为国内企业首个获批上市的盐酸伊立替康脂质体注射液。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首次获批用于胰腺癌一线治疗。目前，该产品用于胰腺癌术后辅助治疗的关键注册III期临床试验正在进行中。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590703195","isCrawlerRequest":true}